Biogen Company Profile (NASDAQ:BIIB)

About Biogen

Biogen logoBiogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: BIIB
  • CUSIP: 09062X10
Key Metrics:
  • Previous Close: $314.81
  • 50 Day Moving Average: $309.56
  • 200 Day Moving Average: $275.71
  • 52-Week Range: $219,120,000.00 - $223.02
  • Trailing P/E Ratio: 18.26
  • Foreward P/E Ratio: 15.00
  • P/E Growth: 1.83
  • Market Cap: $68.49B
  • Outstanding Shares: 219,120,000
  • Beta: 0.9
  • Net Margins: 33.97%
  • Return on Equity: 40.59%
  • Return on Assets: 20.52%
  • Debt-to-Equity Ratio: 0.57%
  • Current Ratio: 2.96%
  • Quick Ratio: 2.56%
Additional Links:
Companies Related to Biogen:

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (?)
Ratings Breakdown: 10 Hold Ratings, 11 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $347.37 (11.13% upside)

Analysts' Ratings History for Biogen (NASDAQ:BIIB)
DateFirmActionRatingPrice TargetDetails
9/22/2016Piper Jaffray Cos.Set Price TargetHold$333.00View Rating Details
9/22/2016Bank of America Corp.Reiterated RatingBuy$374.00View Rating Details
9/20/2016HC WainwrightReiterated RatingBuy$360.00View Rating Details
9/18/2016Credit Suisse Group AGSet Price TargetHold$322.00View Rating Details
9/16/2016JPMorgan Chase & Co.Reiterated RatingBuy$386.00View Rating Details
9/16/2016Stifel NicolausReiterated RatingHoldView Rating Details
9/6/2016Jefferies GroupDowngradeBuy -> Hold$323.00View Rating Details
8/17/2016Morgan StanleyLower Price TargetOverweight$385.00 -> $368.00View Rating Details
8/10/2016Robert W. BairdReiterated RatingNeutral$284.00View Rating Details
8/9/2016Leerink SwannReiterated RatingHold$367.00View Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldView Rating Details
8/2/2016Raymond James Financial Inc.Boost Price TargetStrong-Buy$360.00 -> $375.00View Rating Details
8/1/2016BMO Capital MarketsBoost Price TargetMarket Perform$286.00 -> $304.00View Rating Details
6/29/2016Sanford C. BernsteinInitiated CoverageOutperform$282.00View Rating Details
6/8/2016Royal Bank Of CanadaReiterated RatingBuyView Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/7/2016Citigroup Inc.DowngradeBuy -> Neutral$345.00 -> $295.00View Rating Details
5/26/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/23/2016Goldman Sachs Group Inc.Reiterated RatingHoldView Rating Details
1/27/2016William BlairReiterated RatingOutperformView Rating Details
1/22/2016Barclays PLCReiterated RatingBuy$420.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00View Rating Details
9/23/2015Oppenheimer Holdings Inc.Reiterated RatingSector PerformView Rating Details
8/11/2015Deutsche Bank AGReiterated RatingBuyView Rating Details
7/27/2015ArgusLower Price TargetBuy$450.00 -> $360.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
4/27/2015NomuraReiterated RatingNeutral$401.00 -> $442.00View Rating Details
12/3/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
(Data available from 9/25/2014 forward)


Earnings History for Biogen (NASDAQ:BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.77$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.81$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Biogen (NASDAQ:BIIB)
Current Year EPS Consensus Estimate: $20.10 EPS
Next Year EPS Consensus Estimate: $20.84 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$3.82$4.71$4.40
Q2 20164$4.41$4.74$4.62
Q3 20164$4.49$5.18$4.79
Q4 20164$4.81$5.17$5.07
Q1 20171$5.12$5.12$5.12
Q2 20171$5.19$5.19$5.19
Q3 20171$5.08$5.08$5.08
Q4 20172$4.94$5.06$5.00
(Data provided by Zacks Investment Research)


Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 86.21%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Biogen (NASDAQ:BIIB)
DateHeadline logo[$$] Rodin Therapeutics, a Neurology Drug Firm, Expands Management Team (NASDAQ:BIIB) - September 24 at 8:04 AM logoTop 5 profitable Biotech stocks : September 23, 2016 (NASDAQ:BIIB) - September 23 at 3:18 PM
News IconAnalysts Valuations For Two Stocks: Biogen Inc (NASDAQ:BIIB), Stryker Corporation (NYSE:SYK) - The Voice Registrar (NASDAQ:BIIB) - September 23 at 8:55 AM logoHere's Why Piper Jaffray Remains Sidelined on Biogen Inc (BIIB) - Smarter Analyst (NASDAQ:BIIB) - September 23 at 8:55 AM logoBiogen Bets on Nusinersen (BIIB, IONS) - Investopedia (NASDAQ:BIIB) - September 22 at 3:58 PM
News IconTwo Biotechnology Names Are Hot: Celgene Corporation (CELG), Biogen Inc. (BIIB) - The Independent Republic (NASDAQ:BIIB) - September 22 at 3:58 PM
News IconTwo Biotechnology Names Are Hot: Amgen Inc. (AMGN), Biogen Inc. (BIIB) - The Independent Republic (NASDAQ:BIIB) - September 21 at 3:16 PM
News Icon2 Biotech Stocks News And Price Trends: Biogen Inc. (NASDAQ:BIIB), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - The Voice Registrar (NASDAQ:BIIB) - September 21 at 3:16 PM logoAmazon (AMZN), Charter Communications (CHTR) And 3 Other Hot Stocks That Billionaire Ken Griffin Is Bullish On (NASDAQ:BIIB) - September 21 at 3:16 PM
News IconAnalysts Valuations For Two Stocks: Biogen Inc (NASDAQ:BIIB), Maxim Integrated Products Inc. (NASDAQ:MXIM) - The Voice Registrar (NASDAQ:BIIB) - September 21 at 8:23 AM logoHC Wainwright Weighs in on Biogen Inc (BIIB) Following ECTRIMS Conference - Smarter Analyst (NASDAQ:BIIB) - September 21 at 8:23 AM
News IconHigh Market Cap Stock of the Day – Biogen Inc. (NASDAQ:BIIB) (NASDAQ:BIIB) - September 19 at 4:13 PM logoH.C. Wainwright Weighs in on Biogen Inc (BIIB) Following ECTRIMS Conference (NASDAQ:BIIB) - September 19 at 4:13 PM logoCould This Alzheimer’s Disease Drug Really Be Worth $20 Billion? (NASDAQ:BIIB) - September 19 at 4:13 PM
News IconA look at a High Market Cap Stock: Biogen Inc., BIIB – The Daily ... - The Daily Leicester (NASDAQ:BIIB) - September 16 at 3:48 PM
News IconBiotech stocks for your portfolio: Cempra, Inc. (CEMP), Biogen Inc ... - The Independent Republic (NASDAQ:BIIB) - September 16 at 3:48 PM
News IconBiotech Stocks Worth a Closer Look: Biogen Inc. (NASDAQ:BIIB), Cempra, Inc. (NASDAQ:CEMP) - The Voice Registrar (NASDAQ:BIIB) - September 16 at 12:21 PM logoJP Morgan Comments on Biogen Inc (BIIB) Following Presentation at ECTRIMS Congres - Smarter Analyst (NASDAQ:BIIB) - September 16 at 12:21 PM logoBiogen: You Mean There's Hope? (NASDAQ:BIIB) - September 16 at 12:21 PM
News IconHot Biotech Stocks To Watch Right Now: Biogen Inc. (BIIB), bluebird ... - The Independent Republic (NASDAQ:BIIB) - September 15 at 3:38 PM
News IconNews Highlights- Biogen Inc. (NASDAQ:BIIB), Array BioPharma (NASDAQ:ARRY), Net Element (NASDAQ:NETE) - Seneca Globe (NASDAQ:BIIB) - September 15 at 12:44 PM
News IconA look at a High Market Cap Stock: Biogen Inc., BIIB - The Daily Leicester (NASDAQ:BIIB) - September 15 at 12:44 PM logoNew Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile (NASDAQ:BIIB) - September 15 at 12:44 PM
News IconBiogen Inc. (NASDAQ:BIIB) from Biotechnology – Todays Top Gains (NASDAQ:BIIB) - September 14 at 9:02 PM logoBiogen to Report Third Quarter 2016 Financial Results on October 26, 2016 (NASDAQ:BIIB) - September 14 at 9:02 PM
News IconHC Stocks Impression= Sarepta Therapeutics Inc (SRPT), Biogen Inc (NASDAQ:BIIB) - Cosumnes Connection (subscription) (NASDAQ:BIIB) - September 14 at 3:50 PM
News IconBiogen Inc.'s (BIIB): Leading Stock of Yesterday - Hot Stocks Point (NASDAQ:BIIB) - September 14 at 3:50 PM logoBiogen reports positive new data for multiple sclerosis treatment (NASDAQ:BIIB) - September 14 at 3:50 PM logoNew Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting (NASDAQ:BIIB) - September 14 at 3:50 PM logoBiogen (BIIB) Stock Gains on Positive Multiple Sclerosis Drug Data (NASDAQ:BIIB) - September 14 at 3:50 PM logoBiogen Idec Shares Up 22.3% Since SmarTrend's Buy Recommendation (BIIB) (NASDAQ:BIIB) - September 13 at 5:04 PM
News IconIs Biogen Inc. (NASDAQ:BIIB), a large market cap stock a smart buy? (NASDAQ:BIIB) - September 13 at 5:04 PM logoApplied Genetics’ stock suffers record plunge to record low (NASDAQ:BIIB) - September 13 at 5:04 PM
News IconAnalysts Valuations For Two Stocks: Biogen Inc (NASDAQ:BIIB), Weyerhaeuser Co (NYSE:WY) - The Voice Registrar (NASDAQ:BIIB) - September 13 at 8:43 AM
News Icon2 Biotech Stocks News And Price Trends: Biogen Inc. (NASDAQ:BIIB ... - The Voice Registrar (NASDAQ:BIIB) - September 12 at 3:46 PM logoBiotech: Four Catalysts for Four Stocks (NASDAQ:BIIB) - September 12 at 3:45 PM
News IconHC Stocks Impression= Sarepta Therapeutics Inc (SRPT), Biogen Inc (NASDAQ:BIIB) - share market updates (press release) (NASDAQ:BIIB) - September 12 at 8:36 AM logoBiogen Launches Flixabi To Raise Stakes In Biosimilar Wars (BIIB) - Investopedia (NASDAQ:BIIB) - September 10 at 8:34 AM
News IconRetreated Stocks in Focus- Exelixis, Inc. (NASDAQ:EXEL), Biogen ... - Seneca Globe (NASDAQ:BIIB) - September 9 at 3:46 PM
News IconHot Biotech Stocks Recap: Biogen Inc. (NASDAQ:BIIB), Galena Biopharma, Inc. (NASDAQ:GALE) - The Voice Registrar (NASDAQ:BIIB) - September 9 at 3:46 PM logoBiogen Inc (NASDAQ:BIIB) To Present New MS Data At 32nd ECTRIMS Congress - Market Exclusive (NASDAQ:BIIB) - September 9 at 8:41 AM logoBetter Buy: Biogen Inc. vs. Gilead Sciences - Motley Fool (NASDAQ:BIIB) - September 8 at 3:45 PM logoBiogen: Be Like Celgene? (NASDAQ:BIIB) - September 8 at 3:45 PM logoBetter Buy: Biogen Inc. vs. Gilead Sciences (NASDAQ:BIIB) - September 8 at 11:58 AM logoBiogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio (NASDAQ:BIIB) - September 8 at 8:15 AM logoHC Wainwright Remains Positive on Biogen Inc (BIIB) Following Publication of Phase 1b PRIME Trial - Smarter Analyst (NASDAQ:BIIB) - September 7 at 3:51 PM
News IconBiogen Inc: BIIB Stock is Setting up to Break Out Higher as the Sector turns Bullish - Profit Confidential (NASDAQ:BIIB) - September 7 at 3:51 PM
News IconUpdate on Biogen Inc. (NASDAQ:BIIB) for the day (NASDAQ:BIIB) - September 7 at 12:33 PM logoH.C. Wainwright Remains Positive on Biogen Inc (BIIB) Following Publication of Phase 1b PRIME Trial (NASDAQ:BIIB) - September 7 at 12:33 PM
News IconBiogen Inc: BIIB Stock is Setting up to Break Out Higher as the Sector turns Bullish (NASDAQ:BIIB) - September 7 at 12:33 PM


Biogen (NASDAQ:BIIB) Chart for Sunday, September, 25, 2016

Last Updated on 9/25/2016 by Staff